Novavax Inc.

Novavax Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
382.59 M
Public Float
377.64 M
Novavax Inc.
Stock Exchange NASDAQ Stock Market
EPS
$9.42
Market Cap
$120.42 M
Shares Outstanding
23.47 M
Public Float
378.41 M

Profile

Address
20 Firstfield Road
Gaithersburg Maryland 20878
United States
Employees -
Website http://www.novavax.com
Updated 09/14/2018
Novavax, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the provision of development of recombinant nanoparticle vaccines and adjuvants. Its product pipeline targets infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus, seasonal influenza, pandemic influenza, and Ebola virus. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Financials

View All
Created with Highcharts 5.0.14Novavax Inc.Net Income. Fiscal year is January-December. All values USD Thousands.51 98351 98382 94782 947156 937156 937279 966279 966183 769183 76920132014201520162017050k100k150k200k250k300k
Created with Highcharts 5.0.14Novavax Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.20 91520 91530 65930 65936 25036 25015 35315 35331 17631 17620132014201520162017010k20k30k40k

Stanley C. Erck
President, Chief Executive Officer & Director
John O. Marsh
Director-Emeritus